ArticleSmall (Weinheim an der Bergstrasse, Germany)2026
Disc-Toroid Hybrid Lipid Nanoparticles for Efficient Drug Encapsulation and Subcutaneous Delivery.
Article in Small (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Structural Profiling of Lipid Nanoparticles at Sub-10 nm Resolution via AF4 Coupled Online to SAXS and SANS.Small methods · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The development of effective drug delivery systems for subcutaneous or intradermal injection requires systems with improved bioavailability and biocompatibility. Systematic physicochemical and biological interrogation of carnauba-wax/red-palm-oil lipid nanoparticles (LNPs) stabilized with d-α-tocopheryl-PEG-1000-succinate and polysorbate-40 shows that purposeful matrix engineering yields a robust sub-50 nm carrier for under-skin delivery. Cryo-TEM and SAXS reveal hybrid morphology dominated by 30-40 nm toroidal disc-shaped particles. Orthogonal analytics via multidetection asymmetrical flow field-flow fractionation and WAXS confirm that loading with quinine or dihydroartemisinin leaves size and crystallinity unchanged, achieving approximately 90% encapsulation efficiencies and particle stability up to 18 months at 4°C. Formulations containing red palm oil and the dual-surfactant corona exhibited reduced size dispersity compared with single-component formulations. Long-term viability assays in primary human fibroblasts and macrophages, and ex vivo cultured human skin, underscore excellent biocompatibility up to 0.024% (w/v) lipid. Fluorescein-labeled LNPs traversed the dermis and hypodermis, while only nanomolar lipid concentrations appeared in the receiver medium, indicating a sustained local depot. Overall, this study provides insights into the relationship between formulation composition, particle morphology and measured physicochemical and biological properties relevant to under-skin administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.